DEP lutetium effective in human prostate cancer model
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VivaGel BV launched in central and eastern Europe
- DEP irinotecan phase 2 commences after positive phase 1
- SPL7013 shows significant activity against coronavirus
- Quarterly Cashflow and Activity Report
- Okamoto licenses VivaGel antiviral condom in Asian countries
Later from Starpharma
- DEP products showcased at AACR 2020
- DEP irinotecan boosts immuno-oncology in colon cancer models
- Starpharma signs new DEP partnership with Chase Sun
- SPL7013 nasal spray for COVID19 development update
- SPL creates slow release soluble DEP remdesivir nanoparticle
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma